1] EBMT Lymphoma Working Party, Paris, France [2] BMT Department, Fundeni Clinical Institute, Fundeni Hospital, Bucharest, Romania.
1] EBMT Lymphoma Working Party, Paris, France [2] Department of Hematology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany.
Leukemia. 2015 Mar;29(3):686-8. doi: 10.1038/leu.2014.280. Epub 2014 Sep 19.
The objective of this registry study was to analyse the outcome of patients who underwent allogeneic or autologous haematopoietic stem cell transplantation (HSCT) for hepatosplenic T-cell lymphoma (HSTL), a rare and extremely aggressive peripheral T-cell lymphoma subtype. Patients were eligible if they had histologically verified HSTL and underwent HSCT between 2003 and 2011. Seventy-six patients were identified in the European Society for Bone and Marrow Transplantation database. Additional baseline and follow-up information could be obtained from the referring centres for 36 patients. Eleven of these were excluded following histopathology review, leaving 25 patients in the final study cohort (alloHSCT 18, autoHSCT 7). With a median follow-up of 36 months, 2 patients relapsed after alloHSCT, resulting in a 3-year progression-free survival of 48%. After autoHSCT, 5 patients relapsed and subsequently died. This study indicates that graft-versus-lymphoma activity conferred by alloHSCT can result in long-term survival for a substantial proportion of patients with HSTL.
本研究旨在分析接受异基因或自体造血干细胞移植（HSCT）治疗肝脾 T 细胞淋巴瘤（HSTL）患者的结局，HSTL 是一种罕见且侵袭性极强的外周 T 细胞淋巴瘤亚型。纳入标准为组织学证实的 HSTL 患者，且在 2003 年至 2011 年间接受 HSCT。在欧洲骨髓移植学会数据库中鉴定出 76 例患者，另外 36 例患者可从转诊中心获得更多基线和随访信息。经过组织病理学复查，有 11 例被排除，最终研究队列中包括 25 例患者（alloHSCT18 例，autoHSCT7 例）。中位随访 36 个月后，2 例 alloHSCT 后复发，3 年无进展生存率为 48%。自体 HSCT 后，5 例患者复发并随后死亡。本研究表明，alloHSCT 带来的移植物抗淋巴瘤活性可使相当一部分 HSTL 患者获得长期生存。
